U-PGx Clinican's Questionnaire

U-PGx Clinician`s Questionnaire

 

QUESTIONNAIRE for PHARMACISTS and PHYSICIANS

To whom the questionnaire addresses:

• physicians (treating and dosing patients)


• hospital pharmacists (therapy adjustments, dose adjustments)

 

Introduction

This is an anonymous questionnaire to evaluate the views and knowledge of current drug prescribers on pharmacogenomics and its role in individualizing patient treatment.  This study is part of the work being carried out by a pan-European research collaboration called Ubiquitous Pharmacogenomics (U-PGx: http://upgx.eu/). The results of this questionnaire will support the development of a short e-Learning Tool on pharmacogenomics for clinicians and pharmacists. This questionnaire is anonymous. However, the outcome of the questionnaire will be published in a scientific journal. We are grateful to you for taking the time to answer the following questions.







This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 668353

 

Copy of U-PGx Clinician`s Questionnaire

 

QUESTIONNAIRE for PHARMACISTS and PHYSICIANS

To whom the questionnaire addresses:

• 
  
• physicians (treating and dosing patients)
• 
  
• hospital pharmacists (therapy adjustments, dose adjustments)
• 
  
• 
  
•  

 

Introduction

This is an anonymous questionnaire to evaluate the views and knowledge of current drug prescribers on pharmacogenomics and its role in individualizing patient treatment.  This study is part of the work being carried out by a pan-European research collaboration called Ubiquitous Pharmacogenomics (U-PGx: http://upgx.eu/). The results of this questionnaire will support the development of a short e-Learning Tool on pharmacogenomics for clinicians and pharmacists. This questionnaire is anonymous. However, the outcome of the questionnaire will be published in a scientific journal. We are grateful to you for taking the time to answer the following questions.







This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 668353